Danaher Corporation (DHR) Valuation Exercise

Regeneron was founded in 1988 by Dr. Leonard S Schleifer. Dr. Schelifer shared, that the name Regeneron came from “Regenerating neurons, with the word “gene” in the middle”.  The origin of the name further explains that the initial focus of the company was neurobiology. Then in 1990 following the publication

Founded in 2002, Alnylam has led the commercialization of RNAi. However, the company has faced multiple battles on its way here. After the initial hype of RNA technologies faded in the 2010s, many RNAi companies faced a downturn as the industry quickly lost confidence in the ability to commercialize RNA-based